# Translation

### PATENT COOPERATION TREATY



# **PCT**

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference Y0363-PCT	FOR FURTHER A	CTION	See Form PCT/IPEA/416			
International application No.	International filing da	ate (day/month/year)	Priority date (day/month/year)			
PCT/JP2003/015546	04 December 20	003 (04.12.2003)	05 December 2002 (05.12.2002)			
International Patent Classification (IPC) or national classification and IPC C12N 15/09, C07K 14/47, C12N 1/15, 1/19, 1/21, 5/10, G01N 33/573, A61K 38/17, A61P 5/48						
Applicant YAMANOUCHI PHARMACEUTICAL CO., LTD.						
<ol> <li>This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.</li> </ol>						
2. This REPORT consists of a total of4 sheets, including this cover sheet.						
3. This report is also accompanied by ANNEXES, comprising:						
l —						
sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).						
sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.						
b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s))  disc 1  , containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).						
4. This report contains indications relating to the following items:						
Box No. I Basis of the rep	port					
Box No. II Priority	Box No. II Priority					
Box No. III Non-establishn	Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability					
Box No. IV Lack of unity of invention						
Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement						
Box No. VI Certain documents cited						
Box No. VII Certain defects in the international application						
Box No. VIII Certain observe						
Date of submission of the demand		Date of completion of	this report			
03 March 2004 (03.03.2004)		25 N	May 2004 (25.05.2004)			
Name and mailing address of the IPEA/JP		Authorized officer				
Facsimile No.		Telephone No.				

### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/JP2003/015546

Box No.	I	Basis of the report
1. With other	regard wise in	d to the language, this report is based on the international application in the language in which it was filed, unless indicated under this item.
	This which	report is based on translations from the original language into the following language, ch is language of a translation furnished for the purpose of:
		international search (under Rules 12.3 and 23.1(b))
]		publication of the international application (under Rule 12.4)
		international preliminary examination (under Rules 55.2 and/or 55.3)
furnis	thed to tre not	d to the elements of the international application, this report is based on (replacement sheets which have been to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" to annexed to this report):
	The i	international application as originally filed/furnished
	the d	escription:
	page	, as one many most assuments
	page	
	page	received by this Authority on
	the c	laims:
	page	
:	page	, and the second of the second
	page	
<b> </b>	page	received by this Authority on
	the d	rawings:
	page	, and the state of
	pages	
	pages	received by this Authority on
	a seq	uence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing.
3. 🗌	The a	amendments have resulted in the cancellation of:
		the description, pages
	一	the claims, Nos.
	〒	the drawings, sheets/figs
	一	the sequence listing (specify):
j	Ħ	any table(s) related to sequence listing (specify):
		and the social to social to social string (specify).
4.	made	report has been established as if (some of) the amendments annexed to this report and listed below had not been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box e 70.2(c)).  the description, pages the claims, Nos the drawings, sheets/figs
	님	the sequence listing (specify):
	Ш	any table(s) related to sequence listing (specify):
* If iten	n 4 ap	plies, some or all of those sheets may be marked "superseded."

International application No.

PCT/JP03/15546

Statement			
Novelty (N)	Claims	1-9	YES
	Claims		NO
Inventive step (IS)	Claims	1-9	YES
	Claims		NO
Industrial applicability (IA)	Claims	1-9	YES
	Claims		NO

2. Citations and explanations (Rule 70.7)

Document 1: Y. MITSUUCHI, et al., Oncogene. (1999), Vol. 18, No. 35, p. 4891-4898

Document 2: JP 2003-88388 A (Helix Research Institute) March 25, 2003 & EP 1293569 A2 & US

2003/0219741 A1

Document 3: US 2003/0181366 A1 (V. L. GIRANDA) September 25, 2003 (Family: none)

[Claims 1-9]

The inventions of claims 1-9 involve an inventive step with respect to documents 1-3 cited in the international search report.

Document 1 describes the AKT2 binding protein APPL obtained by yeast two-hybrid screening and it shows that the amino acid sequence of APPL and APPL bind to the inactive form of AKT2.

Document 2 describes an amino acid sequence that has 68% homology with the polypeptide identified as SEQ ID NO: 2 of this application, and 88% homology with the polypeptide identified as SEQ ID NO: 4 of this application (see SEQ ID NO: 2366).

Document 3 describes a peptide that preferably binds with the Akt1 substrate binding site and inhibits the function of Akt.

On the other hand, the applicants disclose an Akt2 binding polypeptide having an amino acid sequence that differs from those of the proteins, polypeptides, and peptides described in documents 1-3, and they discovered that this polypeptide brings about insulin resistance by interacting with Akt2 to reduce the enzymatic activity of Akt2. Because the findings by the applicants are ones that could not be predicted from prior art documents, persons skilled in the art cannot easily conceive of the inventions of claims 1-9.

International application No.

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

PCT/JP03/15546

Supplemental Box Relating to Sequence Listing					
Continuation of Box No. 1, item 2:					
Supplemental Box Relating to Sequence Listing  Continuation of Box No. 1, item 2:  1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this report was established on the basis that of:  a. type of material  a sequence listing  table(s) related to the sequence listing  b. format of material  in written format  in computer readable form  c. time of filing/furnishing  contained in the international application as filed  filed together with the international application in computer readable form  furnished subsequently to this Authority for the purpose of search and/or examination  received by this Authority as an amendment* on					
2. In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed					
or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.					
3. Additional comments:					
* If item 4 in Box No. I applies, the listing and /or table(s) related thereto, which form part of the basis of the report, may be marked "superseded".					